A dose-finding study of the safety of gemtuzumab ozogamicin as a single agent treatment of patients with relapsed acute myelogenous leukemia after autologous or allogenic hematopoietic stem cell transplant

Trial Profile

A dose-finding study of the safety of gemtuzumab ozogamicin as a single agent treatment of patients with relapsed acute myelogenous leukemia after autologous or allogenic hematopoietic stem cell transplant

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2005

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top